Linagliptin fixed-dose combination with metformin is bioequivalent to co- Administration of linagliptin and metformin as individual tablets

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 7, 2014, Pages 537-548

  Buschke, Susanne ^a   Ring, Arne ^a,b,c   Friedrich, Christian ^a   Metzmann, Katrin ^a   Meinicke, Thomas ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Bioavailability; Bioequivalence; Fixed dose combination; Linagliptin; Type 2 diabetes

Indexed keywords

LINAGLIPTIN; LINAGLIPTIN PLUS METFORMIN; METFORMIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; INFECTION; INFESTATION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VITAL SIGN; VOLUNTEER;

ADULT; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; PURINES; QUINAZOLINES; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 84899452185     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201960     Document Type: Article

References (31)

1. Boehringer Ingeiheim Pharmaceuticals GmbH. Tradjenta- (linagliptin) tablets. Available at: http://www.accessdata.fda.gov/drngsatfdadocs/label/2012/ 201280s0051bl.pdf Last accessed Au-gust 16, 2013.
2. Turner RC, Cull CA, Fright V, Holman RR; UK Prospective Diabetes Study (VKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281: 2005- 2012. CrossRel PubMed. (Pubitemid 29254858)
3. Garber AJ, Donovan DS Jr. Dandona P. Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 3598- 3604. CrossRefPubMed. (Pubitemid 37034501)
4. Goldstein BJ, Pans M Rubin CJ. Multicenter, randomized, double-masked, parallel-group as-sessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther. 2003; 25: 890-903. Cross Ref PubMed. (Pubitemid 36459696)
5. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, liberie HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: A randomized, double- blind, placebo-controlled study. Diabetes Obcs Metab. 2012; 14: 565-574. CrossRef PubMed.
6. Benford M, Milligan G, Pike J., Anderson P., Piercv J., Fermer S. Fixed-dose combination anti- diabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012; 29: 26-40. CrossRef PubMed.
7. Cheong C, Burner JC, Lawson KA., Johnsrud MT Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008; 30: 1893-1907. CrossRef PubMed.
8. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J, A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011; 27: 1157-1168. CrossRef PubMed.
9. Pan F, Chemew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008; 23: 611-614. CrossRef PubMed.
10. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012; 51: 411-427. CrossRef PubMed.
11. th San Diego, California, Clinical Pharm in Drug Dev. 2012; 1: 175.
12. Graham GG, Punt J, Antra M, Day RO, Doogue MP, Duong JK, Furlong T.J, Greenfield JR, Greenup LC, Kirkpatriek CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of met-formin. Clin Phannacokinet. 2011; 50: 81-98.CrossRef PubMed
13. Bristol-Myers Squibb Company. Glucophage- (metformin hydrochloride) tablets, Glucophage XR (metformin hydrochloride) extended-release tablets. Available at: http://packageinserts.bms.compi/piglucophage.pdf. Last accessed August 16, 2013.
14. Graefe-Mody EU. Padula S, Ring A, Withopf Dugi KA. Evaluation of the potential for steady- state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009: 25: 1963-1972. CrossRef PubMed.
15. U.S. Department of Health and Human Services FaDA, Centre for Drug Evaluation and Research (CDER). Guidance for industry: bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ ucm070107.pdf. Last accessed August 16, 2013.
16. U.S. Department of Health and Human Services FaDA, Centre for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. AvailabIe at: http://www.fda.gov/downIoads/Drugs/ GuidanceCompiianceRegulatoryInformation/Guidances/ucm070124.pdf. Last accessed August 16, 2013.
17. (EMEA) EMA. Guideline on the investigation of bioequivalence. Available at: http://www, ema, eu-ropa.eu/docs/en-GB/documentlibrary/Scientific-guideline/ 2010/01/WC500070039.pdf. Last accessed August 16, 2013.
18. Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Her bach K, Woerie HJ, Dtigi KA. Linagliptin (BI 1356), a potent and selective DPP- 4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med. 2010; 27: 1409-1419. CrossRef PubMed.
19. Gallwitz B, Rosenstock J, Ranch T, Bhattacharya S, Pate I S, von Eynatten M, Dngi KA, liberie HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet. 2012; 380: 475-483. CrossRef PubMed.
20. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24- week randomized study. Diabet Med. 2011; 28: 1352-1361. CrossRef PubMed.
21. Taskinen MR, Rosen stock J, Tamminen I, Kubiak R, PateIS, Dugi KA, liberie HJ, Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 65-74. CrossRef PubMed.
22. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab. 2003; 29: 79-81. (Pubitemid 36362620)
23. Schectman JM, Nadkarni MM, loss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002; 25: 1015-1021. CrossRef PubMed. (Pubitemid 41110487)
24. Blonde L. Wogen J, Kreilick C. Seymour A A. Greater reductions in A1C in type 2 diabetic pa- Tients new to therapy with glyburide/metformin tablets as compared to glyburide co- Administered with metformin. Diabetes Obes Metab. 2003; 5: 424-431. CrossRef PubMed. (Pubitemid 37483604)
25. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed- dose combination therapy. Clin Ther. 2002; 24: 460-467. CrossRef PubMed. (Pubitemid 34275867)
26. Boehringer Ingelheim International GmbH. Jentadueto™ (linagliptin and metformin hydrochloride) tablets. Available at; http://www.accessdata.fda. govt!rugsatfdadocs/label/2012/201281s000lbl.pdf. Last accessed August 16. 2013.
27. Gomis R, Espadero RM, Jones R, liberie HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 653-661. CrossRef PubMed.
28. Sanofi- Aventis US. LLC. Lantus (insulin glargine (rDNA origin) injection). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2007/02108ls0241bl.pdf. Last accessed Au-gust 16, 2013.
29. Novo Nordisk Inc. Levemir® (insulin detemir (rDNA origin ) injection) solution for subcutaneous injection. Available at: http:/www.accessdata.fda. gov/drugsatfda-docs/label/2012/021536s0371bl.pdf. Last accessed August 16, 2013.
30. Pfizer Inc. Mieronase® glyburide tablets, USP. Available at: http://vvww.accessdata.fda.gov/drugsatfda-docs/label/2011/017498s0301bLpdf. Last accessed August 16, 2013.
31. Lajara R, Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. Expert Opin Pharmacother. 2012; 13: 2663-2671. CrossRef PubMed.